Anti-cancer Effect of Apigenin on Human Breast Carcinoma MDA-MB-231 through Cell Cycle Arrest and Apoptosis

Hwan Hee Lee¹,² and Hyosun Cho¹,²*
¹College of Pharmacy, Dukusung Women’s University, Seoul 01369, Republic of Korea
²Dukusung Innovative Drug Center, Dukusung Women’s University, Seoul 01369, Republic of Korea

Received: September 19, 2018 / Revised: October 9, 2018 / Accepted: October 10, 2018

Introduction

Breast cancer is the most common cancer among women worldwide with a high mortality rate. Breast cancers are classified according to different schemes criteria and the major categories include the histopathological type, the grade, the stage, and the various receptor expressions of cancer. The three major receptors are estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2/neu). Breast cancer with or without these receptors are called ER positive (ER+), ER negative (ER-), PR positive (PR+), PR negative (PR-), HER2 positive (HER2+), and HER2 negative (HER2-) and breast cancer with none of these receptors is called triple negative (TN). The status of these receptors is reported to highly associate with disease progress and clinical outcomes under certain treatments [1, 2]. Triple-negative breast cancer (TNBC) lacking ER, PR, and Her2/neu is known to be about 15–20% of all breast cancer [3]. TNBC is a very aggressive tumor with higher histological grade and is more likely to migrate to distant sites, resulting in poor prognosis [4].

Apigenin (4,5,7-trigutryfrixflavone), a natural flavonoid found in many plants including vegetables, fruits and Chinese herb. The biological activity of apigenin includes antioxidant, anti-inflammatory [5, 6], antibacterial, antiviral and anti-cancer effects [7–9]. Birt et al. reported the tumor inhibition-related effect of apigenin in 1986 for the first time [10]. Apigenin potently inhib-
Apigenin inhibits the epidermal ornithine decarboxylase induction, which highly connected with skin tumor promotion in mice [10]. Since then, anti-tumor activity of apigenin on a variety of cancers such as colorectal cancer, liver cancer, lung cancer, prostate cancer, breast cancer and osteosarcoma has been observed [11–14]. The molecular mechanism of anti-cancer activity of apigenin was found to be related with an inhibition of cell proliferation by arresting cell cycle or induction of cell apoptosis [13, 15]. Also, apigenin seemed to inhibit cell motility and migration [10, 11]. Recently, apigenin showed a strong anti-cancer activity through modulating immune responses against cancer. Cardenas reported that apigenin suppressed leukocyte infiltration by reducing the activation of NF-kB [16]. And, Nelson group showed that apigenin recovered T cell homeostasis and function by increasing the expression of Ikaros in murine pancreatic cancer [17].

The proliferation of cancer cell is known to be regulated by many complicated molecular processes including cell cycle and cell apoptosis. p53 is a representative tumor suppressive protein that plays a critical role in cell apoptosis [18]. And p53 is also one of cell cycle control related proteins along with p21, which is a potent cyclin-dependent kinase inhibitor. The p21 protein is known to directly bind to cyclin-CDKs complexes and inhibits the activity of CDKs [19]. Cell apoptosis associates with not only p53 protein but also caspases and poly ADP-ribose polymerase (Parp) [20]. Caspases are essential proteases that are activated in the process of cell apoptosis. They can be categorized as initiators (caspase -2, -8, -9 and -10) or executioner (caspase -3, -6 and -7) and involves two different apoptotic pathways, the extrinsic and intrinsic pathways [21].

A few studies reported the anti-cancer activities of apigenin on human breast carcinoma MDA-MB-231 [22, 23]. Vrhovac group found that apigenin induced apoptosis, DNA damage and oxidative stress in MDA-MB-231 [22]. Tseng group presented that apigenin inhibited cell proliferation of MDA-MB-231 through up-regulation of p21, which resulted in cell cycle arrest at G2/M phase [23]. However, the further molecular basis of the anti-cancer effect by apigenin still remains to be clarified. In this study, we investigated the cellular anti-cancer mechanisms of apigenin underlying the induction of apoptosis and cell cycle arrest in MDA-MB-231.

**Materials and Methods**

**Specimen preparation**

Apigenin (≥ 95% pure) was purchased from Sigma-Aldrich, Inc. (USA). Apigenin was dissolved using dimethyl sulfoxide (DMSO; Sigma-Aldrich, USA) and diluted with medium for human breast carcinoma MDA-MB-231.

**Cell culture**

Human breast carcinoma MDA-MB-231 was obtained from American Type Cell Culture (ATCC-HTB26). MDA-MB-231 was cultured in RPMI1640 (Corning, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Yong-In Frontier, Korea), 100 U/ml penicillin and streptomycin (Gibco, USA) at 37°C in a humidified atmosphere with 5% CO2.

**MTT assay**

Cell cytotoxicity of apigenin on MDA-MB-231 was assessed using thiazolyl blue tetrazolium bromide (MTT; Sigma-Aldrich, USA). Cells were seeded at a density of 1×10^4 cells per each well in a 96-well flat bottom plate and serially diluted apigenin (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 μM) was added for 24, 48 or 72 h. Then, MTT solution was added to each well, and the cells incubated in accordance with the reactive time of the solution. The absorbance was measured using a microplate reader (BMG Labtech, Ortenberg, Germany) at 570 nm.

**Cell cycle analysis**

Cell cycle was assessed using propidium iodide (Invitrogen, USA) staining assay. MDA-MB-231 was plated in 6-well bottom plate and treated with different concentrations of apigenin (0, 10, 20 and 40 μM) for 24 h. After the treatment, cells were fixed 70% ice-ethanol and stained with propidium iodide (PI) for 15 min at room temperature and then analyzed by flow cytometry (Novocyt® Flow Cytometer, ACEA Biosciences, USA).

**Cell apoptosis analysis**

Cell apoptosis was analyzed by FITC Annexin V Apoptosis Detection Kit I (BD Biosciences, USA). Briefly, MDA-MB-231 was plated in 6-well bottom plate and treated with different concentrations of apigenin (0, 10,
20 and 40 μM) for 24 h. And then, cells were stained with FITC Annexin-V and propidium iodide for 30 min at room temperature. Cell apoptosis was measured by flow cytometry (Novocyte® Flow Cytometer, ACEA Biosciences).

Western blot analysis
MDA-MB-231 was plated with a density of $5 \times 10^5$ per each well in 6-well bottom plate and treated with different concentrations of apigenin (0, 10, 20 and 40 μM) for 24 h. Cells were lysed by protein extraction buffer (Intron Biotechnology, Korea). Proteins in cell lysates were quantified by the Bradford assay, separated by electrophoresis, and transferred to nitrocellulose membranes, which was then blotted with 1st and 2nd antibodies. Anti-PARP (#9542) (and anti-cleaved PARP, #5625), anti-Caspase 3 (#9665) (and anti-cleaved caspase 3, #9664), anti-Caspase 7 (#12827) (and anti-cleaved caspase 7, #8438) and anti-Caspase 9 (#9508) (and anti-cleaved caspase 9, #7237) antibodies and Cell cycle regulation sampler kit (#9932) were obtained from Cell Signaling Technology (USA). Anti-β-actin (#A5441) and anti-p53 (#05-224) antibodies were purchased from sigma Aldrich (USA) and Millipore (USA), respectively. The blots were visualized by enhanced chemiluminescent (ECL) detection solution (Intron Biotechnology, Korea).

Statistical analysis
Data were processed using Microsoft Excel and results are presented as means ± SDs. Comparisons of several means were performed by one-way or two-way analysis of variance followed by Fisher’s exact test to identify significant differences between groups with $p$-values of less than 0.05 being considered significant.

Results and Discussion

Cytotoxic effect of apigenin on human breast carcinoma MDA-MB-231
To identify the cell cytotoxic effect of apigenin on human breast carcinoma MDA-MB-231, cells were treated with serially diluted concentrations (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 μM) of apigenin for 24, 48 and 72 h. Cytotoxicity was determined by MTT assay. Apigenin showed a great cytotoxicity on MDA-MB-231

![Graph](http://dx.doi.org/10.4014/mbl.1809.09006)
Apigenin Inhibits Cell Growth of MDA-MB-231 at 48 or 72 h ($IC_{50} = 54 \mu M$ at 72 h) in a dose dependent manner (Fig. 1A). Fig. 1B shows the morphological changes of MDA-MB-231 under 24 h of treatment with apigenin (0, 10, 20 and 40 μM). As the concentrations of apigenin increased, the proliferation of cells seems to be inhibited even though the $IC_{50}$ value at 24 h was not determined within the range of apigenin concentrations used in this experiment (Figs. 1A and 1B). In fact, the $IC_{50}$ value of apigenin on MDA-MB-231 at 72 h is very close to the $IC_{50}$ value (54.64 μM at 72 h) reported by

![Graph showing cell cycle progression](image)

Fig. 2. Effect of apigenin on cell cycle regulation, p53 and p21 in MDA-MB-231. MDA-MB-231 cells were plated in 6-well bottom plate with a density of $5 \times 10^5$ cells per well and cultured with or without apigenin (0, 10, 20, and 40 μM) for 24 h. For cell cycle assay, cells were stained with propidium iodide (PI), and analyzed using flow cytometry. And, cells were also lysed, and western blot analysis for proteins expression of p53 and p21 is performed. (A) Representative plots of cell cycle progress in MDA-MB-231, (B) the percentage of individual cell cycle distribution from three independent experiments, (C) Expression of p53 and p21 proteins, and (D) relative band intensity of p53 and p21 compared to the loading control.
Vrhovac group [22]. Both studies indicate that apigenin significantly suppresses the cell proliferation of MDA-MB-231 with dose-dependent and time-dependent manner.

**Effect of apigenin on cell cycle regulation, p53 and p21 in MDA-MB-231**

To investigate whether apigenin affects the cell cycle of MDA-MB-231, cells were treated with or without three different concentrations of apigenin (0, 10, 20 and 40 μM). After 24 h, cells were stained with propidium iodide (PI) and analyzed using flow cytometry. As shown in Fig. 2A and 2B, apigenin considerably increased the cell cycle arrest at G2/M phase in a dose-dependent manner (untreated, 25.74%; 10 μM, 31.63%; 20 μM, 36.48%; 40 μM, 38.19%). Apigenin also decreased the G1/S transition although it was not statistically significant (Fig. 2B). Recently, Tseng group also reported that apigenin induced G2/M phase arrest in MDA-MB-231 through upregulation of histone H3 acetylation-mediated p21 expression, which agrees with our result to a certain extent [23]. Furthermore, we examined whether apigenin affects the expression of p53 or p21 proteins because they are known as cell cycle control related proteins as mentioned earlier.

Fig. 2C and 2D shows that the expression of p21 protein is significantly upregulated as the concentration of apigenin increases (Figs. 2C and 2D). Also, the expression of p53 protein seems to be induced by 40 μM of apigenin treatment, which suggests that apigenin induces cell cycle arrest at G2/M phase in p53-dependent manner.

**Effect of apigenin on the expression of CDKs (CDK1,2,4) and Cyclins (Cyclin B1, D1) in MDA-MB-231**

Since apigenin dramatically stimulated the expression of p21 (Figs. 2C and 2D), we determined to examine other cell cycle regulation proteins such as CDK1,2,4, Cyclin B1 and D1, which associate with p21. As shown in Fig. 3A and 3B, the expressions of CDK6, Cyclin D1 and Cyclin B1 proteins are decreased in apigenin treated MDA-MB-231 compared with that from untreated control. Of note, the expressions of Cyclin D1 and Cyclin B1 was almost blocked by 40 μM of apigenin treatment (Figs. 3A and 3B). Interestingly, Cyclin D1 and CDK6 proteins are reported to be overexpressed in several cancers including breast cancer, colorectal cancer, oral squamous carcinoma and brain cancer [24-27]. In detail, Cyclin D1, as a key regulator in cell cycle control, stimulates G1 progression, leading an increase of cell proliferation. Thus, overexpression of cyclin D1 could induce cell proliferation, which results in the development of cancer [24]. CDK6 is also involved in promoting G1 progression and G1/S transition [27]. Cyclin B1 is linked with inducing G2 progression and G2/M transition [28]. And, overexpression of Cyclin B1 has been reported in pancreatic cancer and colorectal cancer [29, 30]. Therefore, our study suggests that apigenin may target both G1/S and G2/M check points by

![Fig. 3. Effect of apigenin on the expression of CDKs (CDK1,2,4) and Cyclins (Cyclin B1, D1) in MDA-MB-231.](http://dx.doi.org/10.4014/mbl.1809.09006)
inhibiting the expressions of Cyclin D1 and CDK6 for G1/S phase arrest and the expression of Cyclin B1 for G2/M phase arrest in MDA-MB-231.

**Effect of apigenin on cell apoptosis in MDA-MB-231**

To investigate whether apigenin affects cell apoptosis in MDA-MB-231, cells were treated with three different concentrations of apigenin (0, 10, 20 and 40 μM) for 24 h and stained with FITC annexin-V and propidium iodide (PI) for apoptotic cells or dead cells, respectively. Fig. 4A and 4B shows that both early and late apoptosis seem to be increased in a treatment with apigenin. Especially, the early apoptosis is significantly enhanced by apigenin treatment in a dose dependent manner compared with that from untreated control (untreated, 4.11%; 10 μM, 9.18%; 20 μM, 11.22%; 40 μM, 13.07%). Of note, 40 μM of apigenin generated up to 20% of apoptosis totally (Fig. 4). In fact, many recent studies reported that apigenin-related flavonoids strongly stimulated cell apoptosis in several cancer cells including various human breast carcinomas, hepatocellular carcinoma and colon cancer [31–33]. Chen group demonstrated that apigenin induced cell apoptosis by inhibiting proteasome activity in MDA-MB-231 and the molecular mechanism of apoptosis was associated with activation of caspase-3 and caspase-7 [34]. Ding found that upregulation of TRAIL pathway is closely connected to the induction of apoptosis by apigenin in MDA-MB-231 [35].

**Effect of apigenin on the expression of (cleaved) parp and caspase-3, 7, 9 in MDA-MB-231**

Since apigenin stimulated cell apoptosis of MDA-MB-231 dramatically with dose dependency (Figs. 4A and 4B). We further analyzed how apoptosis-related cellular molecules are affected by apigenin in MDA-MB-231. We measured the expressions of parp, caspase-3, -7 and -9 as well as the individual cleaved forms because the increased expression of cleaved forms of parp or

![Fig. 4. Effect of apigenin on cell apoptosis in MDA-MB-231.](image) MDA-MB-231 cells were plated in 6-well bottom plate with a density of $5 \times 10^5$ cells per well and cultured with or without apigenin (0, 10, 20, and 40 μM) for 24 h. For apoptosis assay, cells were stained with FITC annexin-V and propidium iodide (PI), and then assessed by flow cytometry. (A) Representative plots of stained cell for apoptosis in MDA-MB-231, and (B) the percentage of apoptotic cell (early and late apoptotic) from three independent experiments.
caspases directly reflects the activation of cell apoptosis. Fig. 5A and 5B shows that there is a clear decrease in the expression of parp, caspase-3 and -9 whereas an increase in the expression of cleaved forms of parp, caspase-3, -7 and -9 by apigenin treatment in MDA-MB-231, which indicates the significant cleavage of parp and caspase-3, -7, and -9. Of note, we observed a strong dose dependency of apigenin in the expression of parp, caspase-3, and -9 (Fig. 5A and 5B). Cao group reported that 40 μM or 80 μM of apigenin induced a considerable cleavage of caspase-3 and parp in MDA-MB-231 [36]. And Chen et al. presented that dose dependent increase of caspase-3/caspase-7 activity by apigenin is positively linked with cell apoptosis of MDA-MB-231 [34]. Both

![Diagram](image1)

**Fig. 6. Anti-cancer mechanisms of apigenin in MDA-MB-231.**

http://dx.doi.org/10.4014/mbl.1809.09006
studies agree with our study and we additionally reported for the first time that caspase-9 is also involved in cell apoptosis of MDA-MB-231.

In this study, we investigated the cell cycle regulation and apoptosis related cellular mechanisms underlying the anti-cancer effect of apigenin in human breast carcinoma MDA-MB-231. Collectively, our data indicates that apigenin has a potent cytotoxic effect on human breast carcinoma MDA-MB-231 through cell cycle arrest at G2/M phase and induction of apoptosis (Fig. 6). In case of cell cycle regulation, apigenin specifically inhibits Cyclin B1, Cyclin D1 and CDK6 proteins along with upregulation of p53 and p21. Apigenin also induces a strong cell apoptosis through cleavage of parp, caspase-3, -7 and -9 in MDA-MB-231. Our study provides a comprehensive understanding of anti-cancer mechanism of apigenin in human breast carcinoma cells, which suggests that apigenin could be a good food supplement for a prevention and treatment against human breast cancer.

Acknowledgments

This research was supported by Duksung Women’s University Research Grants 2018-3000003028.

Conflict of Interest

The authors have no financial conflicts of interest to declare.

References


